beta-secretase

(redirected from Beta secretase)
Also found in: Wikipedia.

beta-secretase

(bā-tă-sē-krĕ-tāz),
Agent that exists in two isoforms; protein with homology to the pepsin family of aspartyl proteases involved in the cleavage of beta-amyloid precursor protein; the gene for this protein is located on chromosome 11.

BACE1

B-site amyloid precursor protein (APP) cleaving enzyme. An aspartic-acid protease encoded by BACE1 on chromosome 11q23.2.-q23.3, which is linked to the pathogenesis of Alzheimer's disease and the formation of myelin sheaths in peripheral nerve cells. BACE1 is a transmembrane aspartic protease (beta-secretase) found in the Golgi apparatus, trans-Golgi network, secretory vesicles, and endosomes. It cleaves amyloid precursor protein (APP) in the brain into amyloid beta peptide, a major component of the amyloid plaques of Alzheimer's disease (AD), the deposition of which is the central pathology in AD, for which BACE1 is potential therapeutic target.
References in periodicals archive ?
announced today that the latest data on its oral dual orexin receptor antagonist lemborexant and its oral beta secretase cleaving enzyme (BACE) inhibitor elenbecestat will be presented at the 10th Clinical Trials on Alzheimer's Disease (CTAD), taking place in Boston, the United States, from November 1 to 4.
announced today that the latest data on its oral dual orexin receptor antagonist lemborexant and its oral beta secretase cleaving enzyme (BACE) inhibitor elenbecestat(1) will be presented at the 10th Clinical Trials on Alzheimer's Disease (CTAD), taking place in Boston, the United States, from November 1 to 4.
The compound deters beta secretase enzyme BACE 1 related to the create of beta amyloid.
and AstraZeneca have entered an agreement to co-develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor in development as a potential treatment for Alzheimer's disease (AD).
Both the AstraZeneca and Merck medicines work by blocking an enzyme called beta secretase that is involved in production of beta-amyloid, a protein that creates brain plaques considered a major cause of Alzheimer's disease.
Pratico said that their research has shown that 12/15-Lipoxygenase controls Beta secretase (BACE-1), an enzyme that is key to the development of amyloid plaques in Alzheimer's patients.
Beta secretase, a protease that cleaves amyloid precursor protein and results in toxic [beta]-amyloid peptides, may also be upregulated by inflammatory mediators.
There is compelling evidence that sAPPbeta, the ectodomain of amyloid precursor protein (APP) shed through beta secretase cleavage, is an important component in the pathogenesis of AD," said Joe Bertelsen, neuroscience product manager, Covance.
The problem with most proposed methods of blocking beta secretase, the study found, is that they are designed to work outside of the affected brain cells.
Over the course of his career, Audia's scientific work has contributed to more than 12 development candidates, including transformative contributions to the treatment of Alzheimer's disease through his discovery of both the first gamma secretase inhibitor and an industry-leading beta secretase inhibitor.
Food and Drug Administration (FDA) has granted Fast Track designation for the development of the beta secretase cleaving enzyme (BACE) inhibitor E2609 which was discovered by Eisai and is being jointly developed by Eisai and Biogen Inc.
announced today that enrollment has commenced in MISSION AD, a Phase III clinical program of the beta secretase cleaving enzyme (BACE) inhibitor E2609 in patients with early Alzheimer's disease in the United States.